Episode 1: ERCP Antibiotics, Apixaban Dose in Cancer, and Early Beta-Blockers in Cirrhosis
Impossibile aggiungere al carrello
Puoi avere soltanto 50 titoli nel carrello per il checkout.
Riprova più tardi
Riprova più tardi
Rimozione dalla Lista desideri non riuscita.
Riprova più tardi
Non è stato possibile aggiungere il titolo alla Libreria
Per favore riprova
Non è stato possibile seguire il Podcast
Per favore riprova
Esecuzione del comando Non seguire più non riuscita
Episode 1: ERCP Antibiotics, Apixaban Dose in Cancer, and Early Beta-Blockers in Cirrhosis
-
Letto da:
-
Di:
A proposito di questo titolo
Send a text
In this pilot episode of Inpatient Update, your host, Dr. Mason Turner, breaks down three clinically relevant studies that could change how you practice tomorrow on the wards:
- Pre-ERCP antibiotic prophylaxis — does it reduce post-procedure infections in biliary obstruction?
- Reduced-dose apixaban after 6 months in cancer-associated VTE — noninferior and potentially safer?
- Early initiation of beta-blockers in cirrhosis with uncomplicated ascites — early signals of benefit.
Practical take-homes, clear links to evidence, and what to tell your team on rounds.
Articles & PubMed Links
- Is Antibiotic Prophylaxis Warranted in All Patients With Biliary Obstruction Undergoing Endoscopic Retrograde Cholangiopancreatography?: A Systematic Review and Meta-Analysis
PubMed: https://pubmed.ncbi.nlm.nih.gov/40961256/ - Extended Reduced-Dose Apixaban for Cancer-Associated VTE (API-CAT)
PubMed: https://pubmed.ncbi.nlm.nih.gov/40162636/ - Efficacy and Safety of Carvedilol in Cirrhosis Patients With New-Onset Uncomplicated Ascites Without High-Risk Esophageal Varices (CARVE-AS Trial)
PubMed: https://pubmed.ncbi.nlm.nih.gov/40689908/
Ancora nessuna recensione